{"doi":"10.1159/000106888","title":"Apolipoprotein E and Alzheimer's Disease: Strength of Association Is Related to Age at Onset","abstract":"<jats:p>Apolipoprotein E (apoE) &amp;#917;4 allele frequency among Alzheimer''s disease (AD) patients is increased compared to control subjects and is influenced by the presence of other genetic factors and age at symptom onset. We examined the relationship between age at AD symptom onset and apoE by comparing the apoE &amp;#917;4 allele frequency of normal, elderly control subjects (n = 107) to that in AD patients (n = 123), divided into four age-at-onset periods. Additionally, the distribution of symptom onset ages of AD patients with and without apoE &amp;#917;4 alleles was determined. We observed increased apoE &amp;#917;4 allele frequencies between the AD onset ages of 55 and 75 years, but not at the extremes of onset ages (i.e. onset between 45 and 54 years of age and after age 75). Our data suggests that having an apoE &amp;#917;4 allele increases the likelihood that AD patients will develop symptoms in the middle range of onset ages. At the extremes of AD onset ages, non-apoE factors, including other genetic factors and age, are more important determinants of risk of developing AD.</jats:p>","journal":"Dementia and Geriatric Cognitive Disorders","year":1996,"id":620649,"datarank":0.47670807455219194,"base_score":3.1780538303479458,"endowment":3.1780538303479458,"self_citation_contribution":0.47670807455219194,"citation_network_contribution":0.0,"self_endowment_contribution":0.47670807455219194,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":23,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1602258,"name":"N.L. Foster","orcid":null,"position":1,"is_corresponding":false},{"id":1602259,"name":"S.P. Kilgore","orcid":null,"position":2,"is_corresponding":false},{"id":1602260,"name":"C.A. McDonagh","orcid":null,"position":3,"is_corresponding":false},{"id":1602261,"name":"J.K. Fink","orcid":null,"position":4,"is_corresponding":false},{"id":1602257,"name":"D.L. Murman","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Apolipoprotein E and Alzheimer's Disease: Strength of Association Is Related to Age at Onset","abstract":"<jats:p>Apolipoprotein E (apoE) &amp;#917;4 allele frequency among Alzheimer''s disease (AD) patients is increased compared to control subjects and is influenced by the presence of other genetic factors and age at symptom onset. We examined the relationship between age at AD symptom onset and apoE by comparing the apoE &amp;#917;4 allele frequency of normal, elderly control subjects (n = 107) to that in AD patients (n = 123), divided into four age-at-onset periods. Additionally, the distribution of symptom onset ages of AD patients with and without apoE &amp;#917;4 alleles was determined. We observed increased apoE &amp;#917;4 allele frequencies between the AD onset ages of 55 and 75 years, but not at the extremes of onset ages (i.e. onset between 45 and 54 years of age and after age 75). Our data suggests that having an apoE &amp;#917;4 allele increases the likelihood that AD patients will develop symptoms in the middle range of onset ages. At the extremes of AD onset ages, non-apoE factors, including other genetic factors and age, are more important determinants of risk of developing AD.</jats:p>","is_dataset_classified":null,"base_score":3.1780538303479458,"endowment":3.1780538303479458,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"8872415","pmcid":null,"openalex_id":"https://openalex.org/W2080104372","authors":[],"funders":[{"funder_name":"NIA NIH HHS","grant_id":"R01-AG10691","title":null},{"funder_name":"NIA NIH HHS","grant_id":"P50-AG08671","title":null}],"total_grants":2,"fwci":0.1861,"citation_percentile":0.50998143,"influential_citations":0,"citation_trend":[{"year":2013,"count":2},{"year":2014,"count":2},{"year":2015,"count":1},{"year":2016,"count":2},{"year":2020,"count":1},{"year":2022,"count":1}],"oa_status":"closed","license":"https://www.karger.com/Services/SiteLicenses","oa_locations":[{"url":"https://www.karger.com/Article/Pdf/106888","host_type":"publisher"},{"url":"https://doi.org/10.1159/000106888","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/8872415","host_type":"repository"}],"fields_of_study":["Alzheimer's disease research and treatments","Dementia and Cognitive Impairment Research","Nuclear Receptors and Signaling"],"mesh_terms":["Aged","Alleles","Alzheimer Disease","Apolipoproteins E","Gene Frequency","Humans","Middle Aged","Age of Onset","Apolipoprotein E4"],"keywords":["Apolipoprotein E","Age of onset","Allele","Alzheimer's disease","Internal medicine","Disease","Degenerative disease","Allele frequency","Medicine","Dementia","Psychology","Endocrinology","Biology","Genetics"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T11:43:02.088692Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}